The Risks and benefits of Glycoprotein IIa / IIIa Inhibitors

These drugs are used to treat possible heart attacks and to prevent clotting during angioplasty, but beware of bleeding risks.

By
estaff
-
Published:
0
Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors are powerful medications that prevent platelets from sticking together and forming a clot. Different GPIIb/IIIa inhibitors-abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat)-are given intravenously before angioplasty or during a suspected heart attack. GPIIb/IIIa inhibitors have been shown to reduce the need for an urgent repeat revascularization, bypass surgery, heart attack or death within 30 days of the procedure in both men and women.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access

RELATED ARTICLESMORE FROM AUTHOR